Article Abstract

The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab

Authors: Sonam Puri, Joseph Markowitz

Abstract

In an elegant study by Weide et al., baseline biomarkers to predict responses to anti-programmed death-1 (PD-1) (pembrolizumab) therapy in melanoma patients were investigated (1).

Refbacks

  • There are currently no refbacks.